8 Indications mapped
8 Trial phases tracked
4 Recruitment statuses visualized
1 At-a-glance competitive view

You Have the Data. You Don't Have the Picture.

Yes, you can ask an AI tool to summarize the clinical trial landscape in your therapeutic area. It will give you paragraphs. It will miss trials, conflate phases, and produce output that your CMO, your VP of BD, and your commercial lead will interpret three different ways. ClinicalTrials.gov contains more than 500,000 registered studies, and a text summary of that data does not tell you where the pipeline is crowded, where Phase 1/2 momentum is building, or which indications have live recruiting pressure right now. Bracken's analytics team built the bullseye to answer those questions in a single auditable view, with every data point sourced directly from ClinicalTrials.gov and visible on the page.

Dermatology Rare Disease Clinical Trial Pipeline

Interactive polar bullseye visualization · Source: ClinicalTrials.gov · Bracken Custom Analytics
Hover over any data point to see trial details. Click legend items to filter by status.

ℹ circa 2022–2023. An updated 2026 version of this chart appears below for direct comparison.

Why comparison matters: Viewing the same therapeutic area across two time points reveals something a single snapshot cannot — directional momentum. Which indications are attracting new investment? Which Phase 2 clusters have advanced to Phase 3? Where has recruiting activity cooled? The delta between two bullseyes is often the most strategically useful output of all.

Built for Any Therapeutic Area

The dermatology example above demonstrates the methodology, but the bullseye approach is fully repeatable across any indication set where ClinicalTrials.gov data exists. Bracken has applied this framework across oncology, rare disease, neuroscience, radiopharma, musculoskeletal, and cardiovascular spaces. Because the underlying data extraction and visualization process is systematized, turnaround is fast, and the output can be updated as the landscape evolves, giving clients a living competitive intelligence tool rather than a static text summary that is outdated the moment it is written.

How the Bullseye Works

The bullseye is a polar chart that arranges indications around the circumference and trial phases along the radius, with trial status encoded by shape and color. The result is a spatial map of a therapeutic area's clinical activity that reveals competitive density, phase progression, and opportunity at a glance.

Define the Therapeutic Area and Indication Set

Bracken's consultants work with the client to define scope: which disease areas, which indications, and which competitive boundaries matter. This step is where consulting judgment shapes the analysis. The same raw data produces very different insights depending on how the map is framed.

Extract and Clean ClinicalTrials.gov Data

Bracken's analytics team queries ClinicalTrials.gov programmatically, pulling all relevant trials by indication, phase, and status. Raw data requires significant cleaning: deduplication, phase normalization, and indication mapping before it is ready for visualization. Proprietary analytics infrastructure makes this process fast and repeatable.

Encode Status, Phase, and Indication Into the Polar Layout

Each trial becomes a data point positioned by its indication (circumferential axis) and phase (radial axis). Recruitment status is encoded by shape: circles for completed trials, squares for actively recruiting, diamonds for not-yet-recruiting, and triangles for active-but-not-recruiting. A single image contains hundreds of data points, readable without a legend once you know the encoding.

Layer in Consulting Interpretation

The visualization is not the deliverable; the interpretation is. Bracken's consultants annotate the bullseye with strategic observations: which indications show early-phase crowding signaling future Phase 3 competition, which areas have Phase 1/2 momentum with no completed trials, and where gaps in the landscape represent differentiation opportunities for the client.

Four Things You Can See That a Table Will Never Show You

Look at the dermatology charts above. Here is what a clinical or BD team can extract in under five minutes — intelligence that would take days to compile from raw ClinicalTrials.gov records.

Where the field is already crowded. Dense Phase 3/4 clusters in Pruritis and Rosacea tell a BD team immediately: late-stage entry in these indications requires an unusually strong differentiation story, or a different patient population. That is a portfolio decision, not a literature review.

Where the next wave is forming. A concentration of Phase 1 activity with few completed trials signals emerging scientific interest before the competitive field has hardened. In this chart, Hidradenitis Suppurativa shows that pattern — a window that will close as recruiting trials advance.

What is about to change. "Active, not recruiting" triangles are trials that have closed enrollment and are approaching data readout. Their results will reshape partnership values, regulatory precedent, and competitive dynamics, often within 12 to 24 months. The bullseye makes them visible at a glance.

Where there is room to move. Sectors with few or no data points, particularly in indications with known disease burden, represent potential white space. In this chart, Radiation-induced Derm is thin across all phases: either an opportunity or a signal that sponsors have tried and retreated. Knowing which requires the next layer of Bracken analysis.

What Clients Receive

An interactive or print-ready polar bullseye chart covering your defined therapeutic area and indication set
A consulting interpretation layer with annotated strategic observations identifying competitive density, white space, and near-term data readouts
Data sourced from ClinicalTrials.gov, cleaned and normalized by Bracken's analytics team
A format readable by clinical, commercial, and BD audiences simultaneously, no data science background required
An updateable output as the landscape evolves, not a one-time static snapshot

AI can summarize the pipeline. A spreadsheet can list it. Neither can show your cross-functional team, in a single image, where the competitive pressure is building, where the white space is, and what is about to change. Bracken's bullseye does. Clinical trial landscape intelligence is only as useful as its format — and that is a competitive advantage in a field where speed and precision of insight directly affect development decisions.

Common Questions About Clinical Trial Landscape Analysis

A clinical trial landscape analysis is a systematic review of all active, completed, and planned clinical trials in a given therapeutic area, typically drawn from ClinicalTrials.gov and supplemented with proprietary intelligence. It maps the competitive environment by phase, indication, and trial status, helping sponsors understand where the pipeline is crowded, where gaps exist, and where differentiation opportunities are greatest.

A bullseye polar chart arranges data points radially around a central axis, making it ideal for comparing multiple categories simultaneously. Applied to clinical trial data, it maps therapeutic indications around the circumference and trial phases along the radius, allowing viewers to immediately see where activity is concentrated, which phases are most crowded, and which indications have early-phase momentum without Phase 3 activity yet.

Bracken's process combines structured data extraction from ClinicalTrials.gov with proprietary analytics tooling and consulting judgment. The team identifies the relevant therapeutic area and indication set, queries and cleans trial data, categorizes trials by phase and recruitment status, and renders the output as a polar bullseye chart. The result is a visual readable at a glance by both clinical and commercial audiences.

A well-constructed pipeline visualization can reveal which indications are approaching Phase 3 saturation (signaling competitive pressure), which early-phase clusters suggest emerging scientific interest, where recruiting trials indicate near-term data readouts, and which disease areas have unmet need with limited current clinical activity. This intelligence informs BD strategy, partnership decisions, trial design differentiation, and investor narrative development.

ClinicalTrials.gov returns a table of individual records, useful for detailed lookup but impossible to interpret at a portfolio or landscape level. Bracken's bullseye approach aggregates, normalizes, and visualizes that data so competitive density, phase distribution, and indication-level momentum become immediately visible. The difference is between a spreadsheet and a map: both contain the same data, but only one lets you navigate.

AI tools can generate landscape summaries, but they produce text, not auditable spatially organized visuals that cross-functional teams can align on. Language models also hallucinate trial details, conflate phases, and cannot guarantee that every registered study in a given indication has been captured. Bracken's bullseye is built from direct, programmatic extraction of ClinicalTrials.gov data, with every data point traceable to a source record. The output is a verified visual, not a generated summary, and the interpretation layer reflects clinical and commercial consulting judgment that AI cannot replicate.

CONTACT US

Consult with our Creative team.

We would be delighted to discuss your goals and share our services.